BioSpace News Archive

Xeris Pharmaceuticals, Inc., a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, announced financial results for the third quarter and nine months ended September 30, 2019.

Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX) is providing a business update and has today announced financial results for the third quarter 2019.

Biotricity Inc. (OTCQB: BTCY), a medical diagnostic and consumer healthcare technology company, today announced financial results for its fiscal second quarter ending on September 30, 2019.

The Lupus Research Alliance (LRA), the largest private funder of lupus research in the world, announced today that 16 studies supported by the organization will be presented at the 2019 ACR/ARP Annual Meeting November 8-13, 2019

FlexEnable, the leader in the development and industrialisation of flexible organic electronics, has acquired Merck’s portfolio of best-in-class, high-performance Organic Thin-Film Transistor (OTFT) materials, including revolutionary and highly-patented organic semiconductors and dielectrics.

SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company delivering innovative therapies for difficult-to-treat and often life-threatening infections, today announced positive top-line results for its Phase 3 VANISH-303 study investigating the safety and efficacy of oral ibrexafungerp as a treatment for women with vulvovaginal candidiasis (VVC).

Correvio Pharma Corp. (NASDAQ: CORV / TSX: CORV), a specialty pharmaceutical company focused on commercializing hospital drugs, today announced that it will report financial results for the third quarter ended September 30, 2019 on Thursday, November 14, 2019.

Industry Veteran Marie E. Lamont Joins Inteliquet as Interim President and Chief Operating Officer

Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention, today announced that Ron Rocca, CEO of Exagen, will be participating in the 13th Annual Canaccord Genuity Medical Technology and Diagnostics Forum on Thursday, November 21 in New York City

Edasalonexent Global Phase 3 PolarisDMD Trial in Duchenne Muscular Dystrophy Fully Enrolled with Top-Line Results Expected in Q4 2020